Skip to main content
. 2016 Aug 1;12(4):3004–3012. doi: 10.3892/ol.2016.4927

Table III.

Number of patients with positive methylation status and clinicopathological data.

MGMT RASSF1A RASAL1 TUSC3
Tissue B L T B L T B L T B L T
Gender
  Female   2/22   1/33   3/33   1/23   0/33   8/33   0/21   1/33   2/33 17/22 12/33 20/33
  Male 0/6 0/9 0/9 0/6 0/9 0/9 0/6 0/9 0/9 2/6 1/9 5/9
Age
  ≤60   2/18   1/23   2/23   0/18   0/23   6/23   0/17   1/23   2/23 10/17   7/23 13/23
  >60   0/10   0/19   1/19   1/11   0/19   5/19   0/10   0/19   0/19   9/11   6/19 12/19
Survival
  Yes 1/8   0/13   1/13 0/9   0/13   2/13 0/8   0/13   0/13 7/9   6/13   11/13a
  No   1/20   1/28   2/28   1/20   0/28   9/28   0/19   1/28   2/28 12/19   7/28   13/28a
Smoking
  Yes   2/26   1/37   3/37   1/27   0/37   9/37   0/27   1/37   2/37 19/26 11/37 22/37
  No 0/2 0/5 0/5 0/2 0/5 2/5 0/2 0/5 0/5 0/2 2/5 3/5
T category
  T1a 0/2 1/8 1/8 0/3 0/8 2/8 0/2 1/8 1/8 3/3 2/8   6/8b
  T1b 0/2 0/2 0/2 0/2 0/2 1/2 0/2 0/2 0/2 0/2 2/2   0/2b
  T2a   1/10   0/16   1/16   1/10   0/16   3/16   0/10   0/16   0/16   8/10   5/16   14/16b
  T2b 0/7 0/8 1/8 0/7 0/8 4/8 0/6 0/8 1/8 5/6 3/8   2/8b
  T3 0/3 0/3 0/3 0/3 0/3 1/3 0/3 0/3 0/3 1/3 0/3   1/3b
  T4 1/4 0/5 0/5 0/4 0/5 0/5 0/4 0/5 0/5 2/4 1/5   2/5b
N category
  N0   2/18   0/28   1/28   0/19   0/28   7/28   0/17   0/28   1/28 14/18   9/28 18/28
  N1 0/8   1/11   2/11 1/8   0/11   3/11 0/8   1/11   1/11 4/8   2/11   5/11
  N2 0/2 0/3 0/3 0/2 0/3 1/3 0/2 0/3 0/3 1/2 2/3 2/3
M category
  M0   2/26   1/38   3/38   1/27   0/38 10/38   0/25   1/38   2/38 19/26 11/38 23/38
  M1 0/2 0/3 0/3 0/2 0/3 1/3 0/2 0/3 0/3 0/2 2/3 1/3
Grading
  G1   1/15   1/24   1/24   0/16   0/24   6/24   0/15   1/24   2/24 11/16 7/24 15/24
  G2   1/13   0/18   2/18   1/13   0/18   5/18   0/12   0/18   0/18   8/12 6/18 10/18
Resection boundaries
  R0 2/26 1/38 2/38 1/26 0/38 11/38 0/25 1/38 2/38 18/26 11/38   25/38c
  R1 0/1 0/3 1/3 0/1 0/3 0/3 0/1 0/3 0/3 1/1 1/3   0/3c
  R2 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 1/1   0/1c
Histology
  AC 1/11 0/17 0/17 0/11 0/17 6/17 0/11 0/17 0/17 6/11 3/17 12/17
  SCC 0/13 1/20 2/20 1/14 0/20 4/20 0/12 1/20 2/20 10/13 9/20 11/20
  LCA 1/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 2/3 1/3 1/3
  Carc 0/1 0/2 1/2 0/1 0/2 1/2 0/1 0/2 0/2 1/1 0/2 1/2
Stage
  I 1/11 0/19 1/19 0/12 0/19 4/19 0/11 0/19 0/19   9/12d 6/19 15/19
  II 0/7 1/10 2/10 1/7 0/10 4/10 0/6 1/10 2/10   6/6d 3/10 4/10
  III 1/8 0/9 0/9 0/8 0/9 2/9 0/8 0/9 0/9   4/8d 2/9 4/9
  IV 0/2 0/3 0/3 0/2 0/3 1/3 0/2 0/3 0/3   0/2d 2/3 1/3

Data are expressed as n/ntotal. Groups with significant P-values from multiple comparison analysis:

a

P=0.039

b

P=0.005

c

P=0.021

d

P=0.041. MGMT, O-6-methylguanine-DNA methyltransferase; RASSF1A, Ras association domain family member 1; RASAL1, RAS protein activator like 1; TUSC3, tumor suppressor candidate 3; B, bronchus; L, lung; T, tumor; T/N/M category, tumor/node/metastasis category; AC, adenocarcinoma; SCC, squamous cell carcinoma; LCC, large cell carcinoma; Carc, carcinoid.